See more : Shanghai Chinafortune Co., Ltd. (600621.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Vir Biotechnology, Inc. (VIR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vir Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Gamelancer Media Corp. (VRTS.TO) Income Statement Analysis – Financial Results
- Alarm.com Holdings, Inc. (ALRM) Income Statement Analysis – Financial Results
- Aveer Foods Limited (AVEER.BO) Income Statement Analysis – Financial Results
- Valaris Limited WT (VAL-WT) Income Statement Analysis – Financial Results
- Galenfeha, Inc. (GLFH) Income Statement Analysis – Financial Results
Vir Biotechnology, Inc. (VIR)
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 86.18M | 1.58B | 1.09B | 67.25M | 711.00K | 868.00K | 149.00K |
| Cost of Revenue | 2.77M | 146.32M | 65.87M | 301.58M | 148.47M | 100.23M | 62.51M |
| Gross Profit | 83.42M | 1.43B | 1.02B | -234.33M | -147.76M | -99.36M | -62.36M |
| Gross Profit Ratio | 96.79% | 90.74% | 93.94% | -348.48% | -20,782.14% | -11,447.12% | -41,854.36% |
| Research & Development | 589.67M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 70.94M | 37.60M | 29.13M | 21.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 174.05M | 161.76M | 160.79M | 70.94M | 37.60M | 29.13M | 21.69M |
| Other Expenses | 0.00 | -35.33M | -8.35M | -9.12M | -7.38M | -212.00K | 83.00K |
| Operating Expenses | 767.72M | 601.09M | 600.45M | 364.23M | 178.69M | 119.56M | 81.65M |
| Cost & Expenses | 770.49M | 747.40M | 666.32M | 364.23M | 178.69M | 119.56M | 81.65M |
| Interest Income | 86.99M | 28.09M | 439.00K | 2.84M | 8.51M | 2.54M | 638.00K |
| Interest Expense | 0.00 | 183.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.45M | 15.49M | 11.98M | 8.81M | 4.52M | 2.76M | 432.00K |
| EBITDA | -664.85M | 833.07M | 420.75M | -289.80M | -173.46M | -115.94M | -81.07M |
| EBITDA Ratio | -771.47% | 59.74% | 26.01% | -441.64% | -25,032.21% | -13,356.68% | -54,406.04% |
| Operating Income | -684.31M | 833.07M | 276.89M | -296.98M | -177.98M | -118.69M | -81.50M |
| Operating Income Ratio | -794.04% | 52.71% | 25.47% | -441.64% | -25,032.21% | -13,674.19% | -54,695.97% |
| Total Other Income/Expenses | 56.11M | -78.79M | 129.05M | -1.63M | 3.45M | 2.33M | 721.00K |
| Income Before Tax | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Before Tax Ratio | -728.93% | 47.72% | 50.58% | -444.06% | -24,546.98% | -13,405.99% | -54,212.08% |
| Income Tax Expense | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income Ratio | -713.69% | 32.64% | 48.62% | -444.14% | -24,568.64% | -13,350.69% | -46,880.54% |
| EPS | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -0.72 |
| EPS Diluted | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -0.72 |
| Weighted Avg Shares Out | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 96.91M |
| Weighted Avg Shares Out (Dil) | 134.13M | 134.81M | 133.44M | 119.16M | 107.65M | 96.91M | 96.91M |
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
Why these stocks could lose money even if the market gains
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
From laggards to leaders: Small caps on the rise
It's Small Stocks' Time To Rally — Analysts Like These 11 Best
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023
Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
Source: https://incomestatements.info
Category: Stock Reports